^
Association details:
Biomarker:ER-CCDC170 fusion
Cancer:Breast Cancer
Drug:lapatinib (EGFR inhibitor, HER2 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance

Published date:
08/08/2020
Excerpt:
More important, breast cancer cells expressing ectopic or endogenous ESR1-CCDC170 are highly sensitive to treatment regimens combining endocrine agents with the HER2 inhibitor lapatinib and/or the SRC inhibitor dasatinib.
DOI:
10.1186/s13058-020-01325-3